After co-administration of micronized fenofibrate and pitavastatin, 10 subjects (41.7% of 24 subjects) experienced 15 reported ADRs, including 4 cases of elevated CPK, 3 cases of increased alanine transaminase (ALT), 2 cases of increased aspartate transaminase (AST) levels, and one case each of decreased WBC, hyperuricemia, increased LDH, abnormal urinary occult blood, abnormal urinary RBC, and diarrhea. The gene discussed is PIK3C2A; the disease is hyperuricemia.